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tate-Mandated Continuing Medical
ducation and the Use of Proven Therapies
n Patients With an Acute Myocardial Infarction
anesh R. Patel, MD,*† Trip J. Meine, MD,*† Jasmina Radeva, MA,* Lesley Curtis, PHD,*
unil V. Rao, MD,*† Kevin A. Schulman, MD,* James G. Jollis, MD*†
urham, North Carolina
OBJECTIVES The purpose of this study was to determine whether state-mandated continuing medical
education (CME) requirements affect the use of evidence-based therapies and outcomes in
patients with acute myocardial infarction (AMI).
BACKGROUND The Institute of Medicine recommends that educational programs demonstrate their effect
through process and outcome measures.
METHODS We analyzed 134,609 patients according to whether or not CME was mandated in the state
of physician practice. A hierarchical multivariable model was developed that controlled for
state, hospital, physician, and patient level characteristics to determine the association
between state CME requirements and the use of evidence-based therapies. Primary outcome
measures were admission aspirin use and reperfusion therapy, and discharge aspirin and
beta-blocker prescription. Thirty-day and one-year mortality were secondary outcome
measures.
RESULTS States with and without CME requirements had similar rates of aspirin use at admission and
discharge (79.9% vs. 79.4% and 72.5% vs. 72.5%, respectively) and beta-blocker prescription
at discharge (53.6% vs. 55.3%). The rate of reperfusion therapy at admission was significantly
higher in states requiring CME (53.1%) compared with states without CME (47.9%) (p 
0.0001). After adjustment, patients admitted in CME-requiring states were significantly
more likely to receive reperfusion therapy, mainly owing to “patented” thrombolytic therapy
(odds ratio 1.15; p  0.016). There was no association between CME requirements and
one-year mortality.
CONCLUSIONS State-mandated CME had little association with AMI care or outcome, other than an
increased use of patented thrombolytic therapy. Further research is needed to maximize the
measurable effect of CME on the use of proven therapies irrespective of whether patented or
generic medications are involved. (J Am Coll Cardiol 2004;44:192–8) © 2004 by the
American College of Cardiology Foundationm
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Ahe Institute of Medicine (IOM), in the recent report
ntitled “Health Professions Education, A Bridge to
uality-2003” (1), makes specific recommendations on the
ontinuing education of health professionals. Specifically,
See page 199
hey recommend that “accreditation bodies move forward
xpeditiously to revise their standards so programs are
equired to demonstrate—through process and outcome
From *Duke Clinical Research Institute, Durham, North Carolina; and †Division
f Cardiology, Duke University, Durham, North Carolina. This work was supported
y the Delmarva Foundation for Medical Care, Inc., and the Centers for Medicare
nd Medicaid Services (formerly the Health Care Financing Administration), U.S.
epartment of Health and Human Services, both in Baltimore, Maryland. The
ontents of this publication do not necessarily reflect the views of the Department of
ealth and Human Services, nor does mention of trade names, commercial products,
r organizations imply endorsement by the U.S. government. The authors assume full
esponsibility for the accuracy and completeness of the ideas presented. This paper is
direct result of the Health Care Quality Improvement Program initiated by the
ealth Care Financing Administration, which has encouraged identification of
uality improvement projects derived from analysis of patterns of care.
Manuscript received December 5, 2003; revised manuscript received March 25,c004, accepted March 30, 2004.easures—that they educate students in both academic and
ontinuing education programs.” The IOM also goes on to
ecommend that “boards should require licensed health
rofessionals to demonstrate periodically their ability to
eliver patient care” through “direct measures of technical
ompetence, patient assessment, patient outcomes, and
ther evidence-based assessment methods” (1). Hence, in an
ffort to improve quality, the IOM is recommending that
tudents and health professionals should be required by
ccreditation agencies to get continuing education, and the
ffects of these programs should be directly measured by
are processes and patient outcomes.
Recognizing the importance of informed physicians,
any states have already mandated participation in continu-
ng medical education (CME) programs as a condition for
edical licensure with the expectation that these programs
ill result in better care. Mandatory CME first came into
xistence in the U.S. in 1934 as a program designed to
nhance the education of urologists. In the 1960s, the
merican Medical Association created an honorary certifi-ate for physicians willing to complete 150 h of CME
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July 7, 2004:192–8 State CME Requirement and AMI Careuring a 3-year period (2). Since that time, the growth of
ME has been exponential. According to data from the
ccreditation Council on Continuing Medical Education
ACCME), in 2002 over 5.4 million physicians and 2.6
illion non-physician health care providers participated in
ME activities at a total cost of over $1.5 billion.
Unfortunately, there is little evidence linking the pre-
umed relationship between a requirement for education
hrough CME programs and a change in physician compe-
ency, performance, and patient outcomes: the specific
andate of the IOM. Therefore, we sought to investigate
he association between state CME requirement and use of
vidence-based therapies and outcomes in patients with
cute myocardial infarction (AMI).
ETHODS
ata source. We used data from the Cooperative Cardio-
ascular Project (CCP). The characteristics of this database
ave previously been published (3). This database, collected
rom 1994 to 1996, contains over 130,000 patients admitted
o hospitals in 46 states nationally with the diagnosis of
MI identified in the Medicare National Claims History
le using the International Classification of Diseases-9th
evision Code. The four states that underwent the original
CP quality improvement project were excluded from the
nalysis. Prespecified demographic, clinical, and treatment
ariables were abstracted from hospital records. Random
harts were re-abstracted to confirm the validity of the
atabase, with overall variable agreement of 95% (3).
Clinical characteristics previously found to influence out-
ome of the patients presenting with AMI were extracted
rom the database. These characteristics included age, gen-
er, socioeconomic status, Killip class, location of the
nfarction, presence of diabetes mellitus, hypertension, and
o not resuscitate orders. These characteristics were assessed
n patients presenting to states with and without CME
equirements.
Information was also collected on hospital-level data for
atients presenting with an AMI in states with and without
ME. These variables included whether the patient was
dmitted to a teaching hospital, a hospital with a catheter-
zation laboratory, and the number of physicians in the
atient’s metropolitan statistical area. Physician-level data
ncluded age, years from medical school graduation, board
ertification, and primary specialty of care.
Abbreviations and Acronyms
ACCME  Accreditation Council on Continuing
Medical Education
AMI  acute myocardial infarction
CCP  Cooperative Cardiovascular Project
CME  continuing medical education
IOM  Institute of Medicine
OR  odds ratioQuality indicators for processes of care for AMI were aeveloped by the Health Care Financing Administration,
ow known as the Centers for Medicare and Medicaid
ervices, in conjunction with the CCP quality improvement
roject (3). These indicators (aspirin use, beta-blocker use,
nd reperfusion therapy—patented thrombolytic or primary
oronary angioplasty) have been validated and incorporated
nto national guidelines of care (4,5). For each indicator,
atients without documented contraindications were iden-
ified as “ideal patients.” These “ideal” candidates for ther-
py were used in the analysis.
Information on states that required CME was obtained
rom the American Medical Association. Individual state
edical boards were contacted to confirm CME require-
ent for the years of 1994 to 1996. During this time period,
2 states mandated CME and 24 states did not mandate
ME.
tatistical analysis. To test for differences between pa-
ients in states with CME requirements and in those
ithout, we used t tests for continuous variables and
hi-square or Fisher exact tests for categorical variables. A
ultivariable model controlling for hospital, physician, and
atient characteristics was developed to examine the asso-
iation between state-mandated CME requirements and
he use of evidence-based therapies. To account for the
atural similarity or clustering within states, we calculated
obust estimates of variance using the method described by
uber (6) and White (7). Because all of the outcomes of
nterest (use of evidence-based therapies, 30-day and 1-year
ortality) were binary variables, we used logistic regression
odels. In each model, the outcome was regressed with
egard to “ideal patient” status, demographics (age, gender,
ace), socioeconomic status (zip code with a median income
200% of poverty level), rural versus urban zip code, patient
edical history (history of previous myocardial infarction,
iabetes mellitus, stroke, dementia, Killip class), hospital
haracteristics (teaching hospital, admission to a hospital
ith a catheterization laboratory), and physician character-
stics (including the total number of physicians in the
atient care). Use of evidence-based therapies and 30-day
nd 1-year outcomes are reported both unadjusted and after
djustment using the multivariable model. Odds ratios
OR) were reported. Statistical analyses were performed
sing SAS Version 8.02 (SAS Institute, Cary, North
arolina) and STATA Version 7.0 (StataCorp, College
tation, Texas).
ESULTS
aseline characteristics of patients with AMI in the 22
tates with CME requirements and in the 24 states without
ME requirements are presented in Table 1. In general, the
roups are similar, with a mean age of 77 years, 47% anterior
ocation of infarcts, and 8% with admission systolic blood
ressure 100 mm Hg. There were slightly more women
nd diabetics admitted to states without a CME require-
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State CME Requirement and AMI Care July 7, 2004:192–8ent (50.4% vs. 49.0%; p  0.0001) and (31.3% vs. 30.3%;
 0.0001), respectively.
Table 2 lists the baseline characteristics of the medical
ystem. There were more admissions to teaching hospitals
n states without CME requirements (41.2% vs. 37.3%; p
.0001). However, states with CME requirements had
ore patients with AMI admitted to hospitals with cardiac
atheterization laboratories (75.6% vs. 70.0%; p  0.0001).
he average age of the physicians taking care of patients was
6 years old. Although cardiologists cared for more patients
n states requiring CME (42.8% vs. 40.3%; p  0.0001),
ore physicians were board certified in states without CME
equirements (81.8% vs. 80.8%; p  0.0001).
The unadjusted quality indicators for AMI in states with
nd without CME requirement are presented in Table 3.
vidence-based quality indicators such as aspirin use on
dmission, beta-blocker use on admission and discharge,
nd smoking cessation counseling were similar in both
roups. In fact, although there was some geographic varia-
Table 1. Baseline Characteristics of Patients
St
Total number of AMI patients, N  134,609
Age, mean (SD)
Female gender, n (%)
Killip class
I, n (%)
II, n (%)
III, n (%)
IV, n (%)
Patients with anterior infarct, n (%)
Patients with SBP 100 mm Hg, n (%)
Patients with median income 200% of
poverty level,* n (%)
Patients with diabetes mellitus, n (%)
Patients with hypertension, n (%)
Patients smoking on admission, n (%)
Patients with do not resuscitate order on
admission,† n (%)
*Socioeconomic status is proxied by an indicator of median inc
variable can be calculated for 62,628 patients in the no CME
were provided by 63,298 patients from the no CME requiri
AMI  acute myocardial infarction; CME  continuing
Table 2. Baseline Characteristics of Medical S
Patients admitted to teaching hospitals, n (%)
Patients admitted to hospital with Cath lab,* n (%)
Physician level†
Age as of 1994
Years from medical school graduation as of 1994
Specialty of MD
Family practice
Internal medicine
Cardiology
Board certified
*Data were provided by 57,518 patients from states wit
†Physician-level information is available for 60,223 admissio
in CME requiring states.Cath lab  catheterization laboratory; CME  continuing meion in the use of evidence-based therapies, rates were
imilar in various regions of the country (Table 4). States
ith a CME requirement were associated with a higher rate
f reperfusion therapy at the time of admission (53.1% vs.
7.9%; p  0.0001). This unadjusted rate was higher for
rimary coronary intervention and patented thrombolytic
herapy use.
After controlling for demographic characteristics, illness
everity, physician, hospital characteristics, and socioeco-
omic status, states with a CME requirement were associ-
ted with a higher rate of reperfusion therapy on admission
OR 1.16; p  0.026) (Table 5). This association was
trongest for reperfusion using patented thrombolytic ther-
py (OR 1.15; p  0.016). Rates of other evidence-based
herapies, aspirin, beta-blocker, and smoking cessation
ounseling were similar in states with and without CME
equirements. Analysis was also performed on 30-day and
ne-year mortality. The unadjusted and adjusted 30-day
nd 1-year mortality were similar in both groups (Table 6).
ith No CME
quirement
States With CME
Requirement p Value
63,299 71,310
7.0 (7.4) 76.9 (7.5) 0.1904
88 (50.4%) 34,914 (49.0%) 0.0001
60 (48.0%) 34,960 (49.0%) 0.0001
30 (12.5%) 8,717 (12.2%) 0.0911
67 (36.6%) 25,584 (35.9%) 0.0059
42 (2.9%) 2,049 (2.9%) 0.6889
79 (47.4%) 33,694 (47.3%) 0.6842
16 (8.1%) 5,651 (7.9%) 0.287
93 (10.2%) 7,311 (10.5%) 0.0639
25 (31.3%) 21,600 (30.3%) 0.0001
52 (61.7%) 44,207 (62.0%) 0.2609
61 (14.5%) 10,532 (14.8%) 0.1242
17 (20.1%) 14,563 (20.4%) 0.1311
n zip code area less than 200% of poverty level. The indicator
and for 69,509 patients in the CME requiring states. †Data
es and 71,310 patients from CME requiring states.
cal education; SBP  systolic blood pressure.
ates With No CME
Requirement
States With CME
Requirement p Value
26,070 (41.2%) 26,610 (37.3%) 0.0001
40,269 (70.0%) 47,618 (75.6%) 0.0001
45.97 (9.1) 46.04 (8.9) 0.0112
19.43 (9.2) 19.45 (9.1) 0.0989
9,576 (15.9%) 8,763 (13.0%) 0.0001
21,030 (34.9%) 23,605 (34.9%) 0.9061
24,285 (40.3%) 28,953 (42.8%) 0.0001
49,286 (81.8%) 54,682 (80.8%) 0.0001
CME and 62,961 patients from CME requiring states.
tates with no CME requirement and for 67,658 admissionsates W
Re
7
31,8
30,3
7,9
23,1
1,8
29,9
5,1
6,3
19,8
39,0
9,1
12,7
ome i
states
ng statystem
St
h no
ns in sdical education.
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July 7, 2004:192–8 State CME Requirement and AMI CareISCUSSION
he IOM has called for direct measurement of education
rograms through care processes and patient outcomes (1). We
erformed an analysis in a large Medicare database (CCP) to
etermine the effect of state-mandated CME requirements on
he use of evidence-based therapies in patients with AMI.
tates with CME requirements did have higher rates of
eperfusion therapy, mainly owing to a higher use of patented
hrombolytic therapy. However, there were no statistically
ignificant differences in other markers of care, including
spirin use (both during index hospitalization and at discharge)
nd beta-blocker use at discharge, after adjustment for patients,
hysician, and hospital-level characteristics. There was also no
Table 3. Unadjusted Use of Evidence-Based T
Acute Myocardial Infarction, n (%)
States Wit
(n 
Aspirin use
During 33,663
At discharge 24,694
Beta-blocker use
During 3,695
At discharge 3,234
Ca channel use at discharge 18,611
Smoking cessation counseling 3,261
Reperfusion at admission 3,138
Primary coronary intervention or
thrombolytics use
3,459
Primary coronary intervention 1,218
Thrombolytics use 2,791
Mortality
30-day 12,976
1-year 22,281
CME  continuing medical education.
able 4. Unadjusted Use of Evidence-Based Therapies and Outc
nfarction, n (%)
States With No CME
East Midwest South
umber of patients 25,157 13,796 17,990
spirin use
During 13,933 (78.7) 7,208 (79.9) 9,003 (79.4)
At discharge 9,900 (70.4) 4,775 (73.8) 6,470 (73.5)
eta-blocker use
During 1,850 (70.6) 583 (56.3) 890 (57.1)
At discharge 1,585 (62.3) 488 (48.7) 745 (48.9)
a channel use at
discharge
6,793 (34.3) 4,275 (39.5) 5,829 (40.9)
moking cessation
counseling
1,112 (37.0) 633 (30.8) 1,122 (35.8)
eperfusion during
stay
1,210 (43.3) 681 (50.5) 838 (49.8)
CI or thrombolytics 1,297 (46.4) 790 (58.6) 929 (55.2)
CI 293 (10.5) 393 (29.1) 367 (21.8)
hrombolytics 1,128 (40.4) 578 (42.9) 743 (44.3)
ortality
30-day 5,057 (20.1) 2,939 (21.3) 3,724 (20.7)
1-year 9,082 (36.1) 4,870 (35.3) 6,261 (34.8)ME  continuing medical education; PCI  primary coronary intervention.ifference in 30-day and 1-year mortality of patients presenting
ith AMI in states with a CME requirement versus states
ithout such a requirement.
Several potential explanations exist for these findings.
ne possibility is that there is a lack of effect of CME on
hysician behavior and practice, or the effect is too small to
e measured with current tools. If the effect of CME cannot
e measured using the detailed data on the rates of
vidence-based therapies in the CCP database, then this has
mportant implications for both the utility of CME and the
OM’s call for outcome measures.
A second possibility is that state CME requirements have
ifferential effects that may represent physician-pharmaceutical
ies and Outcomes in “Ideal” Patients With
CME
9)
CME Requiring States
(n  71,310) p Value
4) 38,297 (79.9) 0.088
5) 27,825 (72.5) 0.9479
3) 3,851 (61.6) 0.0455
3) 3,356 (53.6) 0.0675
2) 21,348 (37.7) 0.0818
6) 3,697 (35.1) 0.4768
9) 3,920 (53.1) 0.0001
8) 4,296 (58.2) 0.0001
6) 1,543 (20.9) 0.0007
6) 3,484 (47.2) 0.0001
5) 14,761 (20.7) 0.4668
2) 24,959 (35.0) 0.5637
by Region in “Ideal” Patients With Acute Myocardial
CME Requiring States
est East Midwest South West
356 9,884 20,307 24,170 16,949
(82.1) 5,724 (80.9) 10,634 (82.2) 12,241 (76.7) 9,575 (81.1)
(76.0) 4,210 (73.1) 7,378 (75.3) 7,939 (68.9) 7,179 (73.5)
(60.0) 747 (78.8) 964 (59.2) 999 (56.3) 1,138 (59.9)
(52.8) 687 (73.5) 809 (51.5) 811 (47.3) 950 (51.3)
(32.7) 2,970 (36.6) 5,906 (36.6) 7,494 (39.9) 4,975 (36.6)
(41.1) 551 (41.3) 1,040 (34.0) 1,167 (30.3) 942 (41.2)
(56.3) 542 (49.4) 1,070 (55.5) 1,237 (52.1) 1,069 (53.9)
(61.0) 569 (51.9) 1,178 (61.1) 1,360 (57.3) 1,190 (60.0)
(23.2) 75 (6.8) 457 (23.7) 520 (21.9) 494 (24.9)
(47.5) 508 (46.5) 917 (47.6) 1,134 (47.9) 911 (46.0)
(20.0) 1,838 (18.6) 4,163 (20.5) 5,317 (22.0) 3,458 (20.4)
(32.3) 3,489 (35.3) 7,047 (34.7) 8,701 (36.0) 5,729 (33.8)herap
h No
63,29
(79.
(72.
(63.
(55.
(37.
(35.
(47.
(52.
(18.
(42.
(20.
(35.omes
W
6,
3,424
2,636
373
324
1,683
398
408
442
168
343
1,271
2,053
i
t
t
l
g
k
s
$
s
s
(
a
T
a
s
r
a
t
a
A
o
C
s
P
s
w
i
t
h
s
t
w
c
m
m
n
p
f
e
i
C
i
b
c
C
i
c
C
t
m
f
o
t
w
a
l
r
p
T
R
O
C
A
B
T
P
T
M
M
*
y
T
N
A
D
D
D
O
196 Patel et al. JACC Vol. 44, No. 1, 2004
State CME Requirement and AMI Care July 7, 2004:192–8ndustry interaction. In this study, the medication most closely
ied to pharmaceutical marketing at the time was thrombolytic
herapy. Unlike aspirin and beta-blockers, patented thrombo-
ytic therapy had a relative lack of competing agents by class or
eneric formulations during the time period, such that mar-
eting efforts were most likely to result in direct revenues to the
ponsoring pharmaceutical firm.
In 2002, industry funding accounted for 60% of the
1.5 billion spent on CME activities (8,9). Industry-
ponsored CME courses have been shown to highlight
ponsors’ drugs and affect physicians’ prescription behavior
10,11). Physician attendance of industry-sponsored CME
ctivities is often associated with academic detailing (12).
he possible synergy between pharmaceutical marketing
nd greater use of evidence-based therapy is of interest. The
imilar rates of aspirin and beta-blocker prescription also
aise concern regarding the ability of CME to improve care
cross all potential interventions, including generic therapies
hat do not represent marketing opportunities. Recently, in
n effort to address the concerns over this interaction, the
able 5. Association Between AMI Admission to a CME
equiring State and Therapies During Admission (“Ideal” Patients
nly, Adjusted for Demographic, State, Socioeconomic, Physician
haracteristics, and Hospital Characteristics)
Therapy n
Odds Ratio
Associated With
Effect of CME
Requiring States
p
Value
spirin use
During 88,351 1.01 0.934
At discharge 68,351 0.98 0.757
eta-blocker use
During 11,888 0.98 0.833
At discharge 11,909 0.97 0.787
otal reperfusion
(primary coronary
intervention or
thrombolytic)
13,672 1.16 0.026
rimary coronary
intervention
13,672 1.06 0.736
hrombolytic 13,645 1.15 0.016
ortality at 30 days* 130,794 1.05 0.388
ortality at 1 year* 130,794 0.99 0.493
The C-index for the multivariable model is C  0.95 at 30 days and C  0.88 at 1
ear.
AMI  acute myocardial infarction; CME  continuing medical education.
able 6. Association Between Admission to a CME Requiring S
N
o adjustment 134,609
djusting for geographic regions 134,609
emographics of patients, adjusting for geographic regions 132,130
emographics of patients, reperfusion Tx, and hospital
characteristics, adjusting for geographic regions
130,794
emographics of patients, reperfusion Tx, and hospital
characteristics and physician-level characteristics
130,794R  odds ratio. Other abbreviations as in Table 5.CCME proposed new regulations to reduce the influence
f the pharmaceutical industry (9).
Another possibility is that the association between a state
ME requirement and reperfusion is related to state-
pecific characteristics of the health care systems in place.
revious studies have found teaching hospitals, physician
pecialty, and possible board certification to be associated
ith greater use of evidence-based therapies (13–15). Thus,
t is potentially feasible that states with greater numbers of
eaching hospitals and board-certified subspecialists might
ave demonstrated superior outcomes unrelated to CME
tatus. However, although our analyses found more admissions
o teaching hospitals and board-certified physicians in states
ithout CME requirements, there were more admissions to
ardiology specialists practicing in states with CME require-
ents. Additionally, significant interaction seems unlikely as
any of the variables were equally distributed in this large
ational database, and our analysis adjusted for these
hysician- and hospital-level factors.
Previous systematic reviews of CME strategies have
ound that traditional didactic sessions have little to no
ffect (16), whereas interactive sessions with practice-based
nterventions may lead to change (17). Indeed, a large
ochrane review of 32 studies on CME also found that
nteractive workshops have a moderate effect on physician
ehavior, whereas didactic sessions alone were unlikely to
hange physician behavior (18). A multifaceted approach of
ME courses and academic detailing by the pharmaceutical
ndustry may approximate interactive sessions and lead to
hange in physician behavior.
We recognize some of the limitations of our analysis. The
ME activities in which the physicians participated during
hat time period may not have been directed toward
yocardial infarction care. Nevertheless, the system in place
or continuing education should have addressed the process
f care for the leading cause of morbidity and mortality in
he U.S. during that time period. Another limitation is that
e cannot be certain that the similarities in medication use
nd outcomes were not due to the attainment of similar
evels of CME by physicians in states without CME
equirements. If state requirements are below levels that
hysicians are likely to attain regardless of mandates, such
nd Mortality From AMI
30-Day Mortality 1-Year Mortality
OR p Value C-Index OR p Value C-Index
1.01 0.4669 0.5012 0.99 0.564 0.5008
1.01 0.6822 0.5012 0.99 0.793 0.5008
1.01 0.714 0.62 1.00 0.867 0.6465
1.05 0.416 0.9505 0.99 0.488 0.8815
1.05 0.388 0.9506 0.99 0.493 0.8816tate a
r
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July 7, 2004:192–8 State CME Requirement and AMI Careequirements will have little effect on improving physician
ducation or patient outcomes.
In a large Medicare database, we found state-mandated
ME requirement was associated with higher rates of
eperfusion therapy, largely because of patented thrombo-
ytic therapy. Although this difference was statistically
ignificant, the absolute difference in reperfusion may not
epresent a clinically significant difference. In addition, there
as no difference in the use of other evidence-based
herapies, such as aspirin and beta-blocker therapy, and no
ifference in mortality at one year. These findings are
ncouraging for a potential improvement in proven thera-
ies for patients with myocardial infarction. However, they
lso raise a concern over differential effects of CME require-
ent on the use of patented therapies versus generic
herapies. Since the time of this large observational study,
he number of states mandating CME has increased from
2 to 34, with some states requiring specific areas of
ompetency. The number of health care providers attending
ME activities and the yearly expenditure continue to rise,
ith over $1.5 billion spent on CME in 2002.
The IOM recommended that students and health pro-
essionals be required by accreditation agencies to get
ontinuing education. However, the recommendation that
he effects of these programs be directly measured by care
rocesses and patient outcomes remains a future goal. Our
tudy utilizing specific rates of evidence-based therapies in a
arge Medicare database was not able to discern a clear
niversal benefit to mandatory CME programs.
We believe that, to achieve the IOM’s stated goals, a specific
ramework needs to be in place to evaluate the effectiveness of
ME programs. The quality indicators for process of care and
utcome measures for patients with AMI have been validated
nd are currently incorporated into national guidelines. How-
ver, there is currently no structure in place to evaluate
erformance based on the specific disease processes or the
ndividual physicians. This would require that CME not only
e disease-specific, but also include minimum quality standards
nd target specific physician specialties.
Therefore, the goal of state-mandated CME should be to
ecome incorporated into each state’s cycle of quality
mprovement. Specifically, quality indicators for the care of
atients with myocardial infarction such as use of evidence-
ased therapies, time to reperfusion, evaluation of left
entricular function, re-admission rates, and in-hospital
omplications as well as mortality should all be collected.
hese indicators could then be used to form these disease-
pecific CME programs. The CME activities of providers
ould then be cataloged and participation related to ob-
erved clinical practice. Feedback would then be given to
linicians, and the findings would help guide the improve-
ent of existing CME programs. In this manner, the
eedback loop would continue to improve CME and phy-
ician behavior. Eventually, CME data in addition to
uality measures could be linked to payer databases to
rovide the final incentive for improvement.Clearly, substantial infrastructure needs to be in place to
valuate the effect of CME. The first step may be rigorous
cquisition of the type and manner of CME activities in
hich physicians are currently participating. Only after this
asic information is collected will progress towards CME
rograms that are disease-specific and physician-specific be
ade. Therefore, investigators and state licensing boards
hould prioritize research on the relationship between CME
nd treatment practices to maximize the measurable effect of
ME on the use of proven therapies irrespective of whether
atented or generic medications are involved.
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